Non-Small Cell Lung Cancer Market Is Likely to Experience a Tremendous Growth by 2029

The global non-small cell lung cancer market is anticipated to grow at a CAGR of 9.6% during the forecast period. The market growth is mainly attributed to the increase in air pollution across the globe. Rising pollution due to the number of carbon particles inhaled by humans causes several problems including lung cancer. The risk is sometimes equivalent to breathing second-hand tobacco smoke and comes from sources like industry, power generation, transportation, and domestic burning. Moreover, smoking cigarettes is also estimated to be one of the major causes of lung cancer among people. According to the reports of the American Cancer Society, In the US, 80% of lung cancer deaths are caused by smoking as the changes in the lung tissue begin almost immediately which damages the line of the lungs. Besides, the rising prevalence of cancer is driving the market growth. For instance, according to the International Agency for Research on Cancer, in 2020, there was around 227,875 lung cancer patient in theUS and it is estimated to reach at around 314,015 by 2040. 

In addition to this, radiation, exposure to radon gas, certain metals, and some organic chemicals are some of the other factors that lead to lung cancer-causing the growth of the treatment of lung cancer. Government organizations and initiatives also play a major role in the treatment of lung cancer to increase the survival rate. For instance, in May 2020, FDA approved CYRAMZA in combination with erlotinib for the treatment of metastatic non-small cell lung cancer (NSCLC). Moreover, in the same month, FDA also improved Roche’s Tecentriq for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression. In addition to this, in January 2020, Bristol Myers Squibb received European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy for first-line treatment of metastatic Non-Small Cell Lung Cancer.

To Request a Sample of our Report on Non-Small Cell Lung Cancer Market:  https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market

Market Coverage

·        The market number available for – 2022-2030

·        Base year- 2022

·        Forecast period- 2023-2030

Segment Covered- 

·        By Type 

·        By Therapy

·        By Diagnosis

·        By End-User

Regions Covered-

·        North America

·        Europe

·        Asia-Pacific

·        Rest of the World

Competitive Landscape- Eli Lilly and Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca PLC, Novartis AG, and Bristol Myers Squibb Co., among others

Non-Small Cell Lung Cancer Market Segmentation

By Type

·        Adenocarcinomas

·        Squamous Cell Carcinoma

·        Large Cell Carcinomas

·        Others

By Therapy

·        Chemotherapy

·        Targeted Therapy

·        Radiation Therapy

·        Surgery

·        Cryosurgery

·        Others

 By Diagnosis

·        CT Scan

·        X-Rays

·        Sputum Cytology

·        Bronchoscopy

·        Laboratory Tests

·        Thoracoscopy

·        Others

By End-User

·        Multispeciality Hospitals

·        Cancer Research Centers

A full Report of Non-Small Cell Lung Cancer Market is Available @  https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market

Regional Analysis

North America

·        United States

·        Canada

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan

·                  South Korea

·                  Rest of APAC

Rest of the World

Company Profiles 

·        AbbVie Inc.

·        Agena Bioscience, Inc.

·        Arqule Inc.

·        Amgen Inc. 

·        AstraZeneca PLC

·        Bayer AG

·        Biodesix, Inc.

·        Boehringer Ingelheim International GmbH

·        Bristol Myers Squibb Co.

·        DAIICHI SANKYO CO. LTD.

·        Eli Lilly and Co. 

·        Exosome Diagnostics Corp.

·        F. Hoffman-La Roche, Inc.

·        Genentech, Inc. 

·        GlaxoSmithKline PLC

·        Illumina, Inc.

·        Merck & Co., Inc.

·        Novartis International Ag

·        Personal Genome Diagnostics Inc.

·        Pfizer Inc.

·        Qiagen NV

·        Sanofi SA

·        SAGA Diagnostics AB

·        Thermo Fisher Scientific Inc.

Reasons to buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/non-small-cell-lung-cancer-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404